Clinical Trials Browser

Interleukin 1 Receptor Antagonist Protein × 90 days × Clear all

NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Phase 2 Terminated

Lymphoma, Large B-Cell, Diffuse, Disease Progression

NCT02021422 2026-02-18

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms